Weizmann Institute Using GSI Technology’s Gemini-I® APU to Accelerate Search for Coronavirus Treatments
August 06 2020 - 6:00AM
GSI Technology, Inc. (Nasdaq: GSIT), a leading
provider of high-performance memory solutions for the networking,
telecommunications and military markets, and developer of the
Gemini® Associative Processing Unit (APU), published a white paper
on GSI Technology’s role in helping researchers at the Weizmann
Institute in the search for COVID-19 treatments.
The white paper discusses how the Weizmann
Institute is using the Gemini APU, GSI's patented in-memory
processing technology, to search for active chemical structures,
including compounds that can target the coronavirus. This new breed
of processor performs massive parallel data processing, compute,
and search directly in the memory array.
Lee-Lean Shu, Chairman and Chief Executive Officer
of GSI Technology, commented, "We are excited to be working with
the Weizmann Institute to accelerate the discovery of active
compounds that may prove useful in COVID-19 treatments. The
Gemini-I APU is being used by researchers to identify compounds
structurally similar to Remdesivir, an antiviral drug recently
shown to be effective in treating severe COVID-19 patients.
Compared to a CPU, our processor speeds up discovery by performing
multiple versus solitary searches and reducing response times from
many minutes to seconds."
Researchers at the Weizmann Institute of Science,
in Rehovot, Israel, and The Nancy & Stephen Grand Israel
National Center for Personalized Medicine (G-INCPM), which is based
at and managed by the Weizmann Institute, have installed a board
with the GEMINI-I APU. G-INCPM's multidisciplinary teams of
scientists and clinicians, working in collaboration with biomedical
and pharmaceutical companies, conduct research involving genomics,
protein profiling, bioinformatics, and drug discovery, translating
those insights to the clinic for the benefit of human health.
A central premise of medicinal chemistry is that
structurally similar molecules exhibit similar biological
activities. The coronavirus (SARS-CoV-2) is related to SARS-Cov,
responsible for the SARS outbreak of the early 2000s. Remdesivir is
an antiviral drug that has been shown in laboratory tests to be
effective against SARS-Cov. Weizmann researchers, working with the
Gemini APU and using Remdesivir as their query molecule, can
perform very rapid similarity structure searches on an in-house
database of 40 million compounds in their search for compounds to
develop new treatments for COVID-19 patients.
Please use this link to view the Company’s
publication “Introducing a “Cheminformatics Similarity Structure
Search Solution”
https://www.gsitechnology.com/Introducing-a-Cheminformatics-Similarity-Structure-Search-Solution.
ABOUT GSI TECHNOLOGY
Founded in 1995, GSI Technology, Inc. is a leading
provider of semiconductor memory solutions. GSI’s resources are
currently focused on bringing new products to market that leverage
existing core strengths, including radiation-hardened memory
products for extreme environments, and Gemini, the APU designed to
deliver performance advantages for diverse artificial intelligence
applications. GSI Technology is headquartered in Sunnyvale,
California and has sales offices in the Americas, Europe, and
Asia. For more information, please
visit www.gsitechnology.com.
Contacts:Investor Relations:Hayden
IR Kim Rogers 385-831-7337
Company:GSI Technology, Inc.
Douglas M. Schirle Chief Financial Officer 408-331-9802
GSI Technology (NASDAQ:GSIT)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSI Technology (NASDAQ:GSIT)
Historical Stock Chart
From Sep 2023 to Sep 2024